Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L17 pseudogene 26 (RPL17P26)
- Target
- RPL17P26
- Molecular classification
- Other (Pseudogene)
01
Overview
Ribosomal protein L17 pseudogene 26 (RPL17P26) is a processed pseudogene corresponding to the ribosomal protein L17 gene. Pseudogenes arise from retrotransposition or gene duplication events and lose the ability to code for functional proteins due to mutations such as frameshifts or premature stop codons. RPL17P26 is annotated in gene databases as a non-functional relic of the ribosomal protein L17 gene and does not encode a protein; it has no known biological activity or disease association. Pseudogenes like RPL17P26 serve as records of evolutionary history and can complicate genetic analyses due to their sequence similarity to functional genes.
- Other names
- RPL17P26RPL17_14_707
02
Mechanism of action
None (not targeted pharmacologically)
03
Biological functions
None (as a pseudogene, no direct biological function)
04
Disease associations
None (no direct involvement in disease, but functional ribosomal protein genes like RPL17 have disease links such as anemia, not applicable to this pseudogene)
05
Safety considerations
None (not therapeutically targeted)
06
Interacting drugs
None (not a protein, so no drug interaction)
07
Biomarkers
None reported
Beyond the preview
Go deeper on Ribosomal protein L17 pseudogene 26 (RPL17P26).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ribosomal protein L17 pseudogene 26 (RPL17P26).